October 5, 2006 -- Dynavax rose 55% after positive trial results of its anti-ragweed therapy, Tolamba, were published in a journal article; GlaxoSmithKline won FDA approval of its FluLaval vaccine; Merck and Schering-Plough reported their anti-cholesterol drug, Vytorin, can say it is more effective than Crestor; Prana will begin a Phase IIa trial of its Alzheimer’s drug; Alkermes licensed rights to opioid receptor compounds from Rensselaer; GTC received a $1.4 million grant to fund research of a drug for solid tumors and autoimmune diseases; the FDA approved the contraceptive Yaz from Schering for premenstrual dysphoric disorder; Dyax will discover compounds that bind to targets identified by Trubion; GenVec will receive up to $52 million over five years to develop an HIV vaccine; and Trimeris reported that Fuzeon, together with a Merck drug, reduced HIV levels to undetectable levels. The Centient Biotech 200™ gained 53 points to 3897.56, an increase of 1.39%, far outpacing the broad market. More details...
